Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome

Keyphrases

• Anakinra 100%
• Cytokine Storm 100%
• Macrophage Activation Syndrome 100%
• Calm 100%
• Adult Patients 33%
• Serologic 33%
• Therapeutic Approaches 16%
• Severe Disease 16%
• Demographic Characteristics 16%
• Clinical Characteristics 16%
• Hemophagocytic Lymphohistiocytosis 16%
• Continuous Infusion 16%
• Clinical Response 16%
• Retrospective Chart Review 16%
• COVID-19 Pandemic 16%
• No Recurrence 16%
• Clinical Improvement 16%
• Interleukin-1 Receptor Antagonist (IL-1Ra) 16%
• Laboratory Features 16%
• Severely Ill 16%
• Severely Ill Patients 16%
• Laboratory Outcomes 16%
• Canakinumab 16%

Medicine and Dentistry

• Infusion 100%
• Anakinra 100%
• Macrophage Activation Syndrome 100%
• Cytokine Storm 100%
• Disease 16%
• Recurrent Disease 16%
• Continuous Infusion 16%
• COVID-19 16%
• Hemophagocytic Syndrome 16%
• Interleukin 1 Receptor Blocking Agent 16%
• Canakinumab 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Macrophage Activation Syndrome 100%
• Anakinra 100%
• Cytokine Storm 100%
• Recurrent Disease 16%
• Pandemic 16%
• Interleukin 1 Receptor Blocking Agent 16%
• Hemophagocytic Syndrome 16%
• Disease 16%
• Canakinumab 16%